CooperVision’s research and development team, led by Senior Director of Research Programs Paul Chamberlain, along with their coauthors, has once again received the prestigious Garland W. Clay Award, presented annually by the American Academy of Optometry. This marks the second time in four years that CooperVision’s pioneering work in myopia control has received the honor, underscoring the company’s enduring leadership and impact in advancing eye health worldwide.
The 2025 award recognizes the paper, “Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial” (Chamberlain P. et al.), published in Optometry and Vision Science (OVS). The award honours the authors of the most significant paper in OVS over the past five years: Paul Chamberlain, Arthur Bradley, Baskar Arumugam, David Hammond and John McNally, CooperVision; Nicola S. Logan, Aston University, United Kingdom; Deborah Jones, University of Waterloo, Canada; Cheryl Ngo, National University Hospital, Singapore; Sofia C. Peixoto-De-Matos, University of Minho, Portugal; Chris Hunt and Graeme Young, Visioncare Research, United Kingdom.
“I am incredibly honoured, along with my coauthors, to receive the Garland W. Clay Award for a second time in such a short period,” said Chamberlain. “We are passionate about sharing the MiSight 1 day study findings with the global eye care professional community, presenting research that is balanced, clinically meaningful, and practical, which are all values Garland Clay championed. This recognition also belongs to the investigators, staff, children and their families whose long-term commitment was essential to every insight we’ve shared.”
This six-year publication, the second installment in the trilogy of landmark MiSight 1 day clinical trial papers, demonstrated the sustained treatment effect of the lens in slowing myopia progression, reinforcing its clinical value.*[1] It follows the three-year results paper, which earned the 2021 Garland W. Clay Award, and precedes the publication of the findings of the final year of the seven-year study, completing the longest continuous international investigation of its kind for myopia control soft contact lenses among children. Collectively, the trilogy provides unmatched evidence of MiSight 1 day’s safety[2] and effectiveness in slowing the progression of myopia in children.[3]
Award Presentation and Industry Impact
“To be recognized with the Garland W. Clay Award for a second time is an extraordinary testament to the quality, impact, and enduring relevance of our research,” said Jennifer Lambert, Vice President, Myopia Management & Cornea Care, CooperVision. “This three-part study not only shaped the global scientific conversation around myopia management but also translated into real-world benefits for children and families worldwide.”
The American Academy of Optometry will formally present the 2025 Garland W. Clay Award to the authors on Friday, October 10, during its annual meeting in Boston. The publication is available online via Open Access.
# # #
* While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.
Canadian Indications for Use: MiSight (omafilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study. Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MiSight (omafilcon A) Soft Contact Lenses for Myopia Control are indicated for single use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.
[1] Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci. 2022 Mar 1;99(3):204-212.
[2] Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391.
[3] Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. OVS 2019; 96(8):556-567.
